Alimta and Avastin for ovarian cancer – pro
was able to find one small phase II trial of thsi combination, that, however, concluded:”Combination bevacizumab/pemetrexed is an active option for both platinum-sensitive and -resistant recurrent EOC. Further investigation of cost and novel toxicities associated with this regimen may be warranted.”. Clearly, more work on this tegimen remains to be done.
© 2013.
David S. Miller, John A. Blessing, Carolyn N. Krasner, Robert S. Mannel, Parviz Hanjani, Michael L. Pearl, Steven E. Waggoner and Cecelia H. Boardman, Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group. JCO June 1, 2009 vol. 27 no. 16 2686-269
NCCN, Ovarian 2016
Hagemann AR, Novetsky AP, Zighelboim I, et al: Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer. Gynecologic Oncology 2013;131:535-540.